Trials / Completed
CompletedNCT03071133
Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy
Asunaprevir/Daclatasvir/Beclabuvir Fixed-Dose Combination Safety Surveillance in Japanese Patients With Chronic Hepatitis C (HCV) or Japanese Patients With Compensated Cirrhosis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 344 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
An observational, postmarketing commitment following the marketing authorization for DCV Trio therapy in Japan
Conditions
Timeline
- Start date
- 2018-01-01
- Primary completion
- 2019-01-08
- Completion
- 2019-01-08
- First posted
- 2017-03-06
- Last updated
- 2022-02-23
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03071133. Inclusion in this directory is not an endorsement.